Brokerages Set Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Target Price at $8.75

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $8.75.

Several brokerages recently weighed in on AUTL. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Weiss Ratings downgraded shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday.

Institutional Trading of Autolus Therapeutics

Several large investors have recently made changes to their positions in the stock. Alphabet Inc. acquired a new position in shares of Autolus Therapeutics during the 2nd quarter valued at about $1,117,000. Syncona Portfolio Ltd acquired a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $26,625,152,000. Hennion & Walsh Asset Management Inc. lifted its holdings in Autolus Therapeutics by 2.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after purchasing an additional 11,197 shares during the last quarter. GAMMA Investing LLC boosted its position in Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after purchasing an additional 8,309 shares during the period. Finally, Waverly Advisors LLC bought a new stake in Autolus Therapeutics during the first quarter worth approximately $37,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $2.11 on Friday. Autolus Therapeutics has a one year low of $1.17 and a one year high of $2.52. The business’s 50-day moving average price is $1.59 and its two-hundred day moving average price is $1.54. The company has a market capitalization of $561.60 million, a P/E ratio of -1.94 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%. On average, equities analysts anticipate that Autolus Therapeutics will post -0.86 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.